Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
M&A / Property

Ynvisible Interactive receives supply LOI from Sapphiros

By The Northwire Desk — AI Analysis Mar 11, 2026 · 10:36 YNV · 0.12 Ynvisible Interactive Inc
YNV · Price

Executive Summary

  • Ynvisible Interactive Inc. received a letter of intent from Sapphiros to become the exclusive supplier of its e‑paper displays for Sapphiros’s next‑generation lateral flow and molecular diagnostic tests.
  • The LOI outlines a three‑year exclusive supply agreement, with commercial sales expected to commence in 2026 and accelerate thereafter.
  • This partnership marks Ynvisible’s first large‑scale entry into the high‑volume medical diagnostics market, potentially unlocking significant revenue growth.

Key Details

  • Letter of Intent (LOI): Received from privately held consumer diagnostics company Sapphiros; outlines intent to enter a three‑year exclusive supply agreement for Ynvisible e‑paper displays.
  • Regulatory Status: Clinical studies for Sapphiros’s digital lateral flow tests are ongoing; regulatory approvals pending.
  • Commercial Timeline: Initial sales of Ynvisible displays to Sapphiros expected in 2026, with acceleration throughout the year as products launch commercially.
  • Scope of Supply: Exclusive provision of ultralow‑power, thin, flexible e‑paper displays for both point‑of‑care and direct‑to‑consumer diagnostic platforms (respiratory and other rapid tests).
  • Strategic Significance: First commercial business for Ynvisible in the global medical diagnostics sector; anticipated expansion to additional customers within this market.
  • Joint Development History: Collaboration began in 2024, during which Ynvisible engineered customized display solutions for Sapphiros’s diagnostic platforms.
  • Market Opportunity: High‑volume medical and diagnostic applications are expanding as healthcare systems adopt decentralized testing; Ynvisible’s technology is positioned to meet low‑power, cost‑sensitive requirements.

Notable Quotes

  • “This letter of intent represents an important step toward commercial deployment of Ynvisible's technology in next‑generation diagnostic devices,” – Ramin Heydarpour, CEO & Chairman, Ynvisible Interactive Inc.
  • “Our partnership with Ynvisible empowers users of our diagnostic devices…with clear, visible results, offering confidence in understanding test outcomes,” – Mark Gladwell, CEO, Sapphiros.
Read the original news release →

More from Ynvisible Interactive Inc

Jun 10, 2026 · 02:01

Low-volume commercial execution continues to outpace revenue recognition in a cash-burn, going-concern environment.

Production / Operations Jun 04, 2026 · 15:26

Ynvisible extends private placement deadline to July 2026 as it pursues medical and automotive e-paper growth

Financings May 28, 2026 · 14:24

Ynvisible Secures Incremental Grant Funding Amidst Continued Dilution and Commercial Scaling Phase

Production / Operations May 13, 2026 · 17:17

Ynvisible Secures Insider-Backed Capital at Premium to Market Amidst Downtrend

Financings Apr 24, 2026 · 15:51

Ynvisible Secures Working Capital Amidst Dilution Concerns and Commercial Ramp-Up

Financings Mar 31, 2026 · 16:12

Ynvisible Closes Tranche Two of Dilutive Financing as Cash Burn Outpaces Commercial Traction

Financings